Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Membrane integral NOTCH2-associated receptor 2 (MINAR2) is a membrane protein essential for normal hearing in humans and mice, encoded by the MINAR2 gene[1][2]. MINAR2 is highly expressed in the cochlear hair cells, spiral ganglia, spiral limbus, and stria vascularis of the inner ear, where it supports proper auditory function without being required for hair cell survival during early development. Loss-of-function variants in MINAR2 cause autosomal recessive, nonsyndromic sensorineural hearing loss due to progressive disruption of cochlear hair cell synapses and stereocilia organization. Mechanistically, MINAR2 acts as a negative regulator of NOTCH2 signaling, downregulates VEGFA, and inhibits mTOR and MAP kinase pathways. No drugs are currently known to target MINAR2, but its restricted function and preserved hair cells in mutant animals make it a candidate for genetic therapies for hereditary deafness[1][2].
No drugs targeting MINAR2 are currently described; mechanistic studies suggest its activity involves suppression of NOTCH2, VEGF, mTOR, and MAP kinase (ERK1/2) pathways[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Membrane integral NOTCH2-associated receptor 2 (MINAR2).